"Scanxiety" is a significant emotional challenge for cancer patients, affecting life planning and inducing stress during medical imaging procedures. Small acts of kindness from healthcare ...

Rybrevant plus chemotherapy significantly improves progression-free survival in relapsed, advanced EGFR-mutant non-small cell lung cancer. The treatment is approved in Europe and pending FDA approval, ...

Extended lymphadenectomy did not improve disease-free or overall survival compared to standard lymphadenectomy in muscle-invasive bladder cancer patients. Higher perioperative morbidity and mortality ...

Overcoming testicular cancer, the protagonist finds strength in marathon training, emphasizing perseverance and self-discovery. Friendship plays a crucial role, with Joe providing support and ...

The poem reflects a parent's emotional turmoil when torn between two children's needs during a cancer battle. It highlights the guilt and longing felt while being physically absent from one child but ...

PCV plus radiation improved overall and progression-free survival compared to TMZ plus radiation in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma patients. Five-year overall survival was 89% ...

Jenna Fischer highlighted early detection's role in her breast cancer recovery, stressing the significance of routine mammograms. Martha Davis canceled concerts due to breast cancer treatment, having ...

A high PD-L1 score suggested immunotherapy, yet cisplatin chemotherapy was chosen, raising questions about treatment decisions. The patient experienced severe side effects from chemotherapy, ...

Itovebi is approved for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after adjuvant endocrine therapy recurrence. The INAVO120 trial showed Itovebi improved progression-free ...

Dato-DXd significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. The study showed a 37% reduction in disease progression or ...

SBRT and hypofractionated CRT showed similar effectiveness and low severe side effects in stage 1 NSCLC treatment. SBRT delivers higher radiation doses in fewer sessions, while hypofractionated CRT ...

The phase 1b BRUIN trial showed high response rates for PV (93.3%) and PVR (100%) in r/r CLL patients. Eighteen-month progression-free survival rates were 92.9% for PV and 80% for PVR, indicating ...